The Medical Letter on Drugs and Therapeutics
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a once-weekly extended-release formulation of exenatide (Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.

MECHANISM OF ACTION — GLP-1 is released from cells in the gastrointestinal tract in response to food. It potentiates insulin secretion, lowers serum glucagon concentrations, slows gastric emptying and promotes satiety. In patients with diabetes, administration of a GLP-1 agonist results in lowering of fasting blood glucose and reduction of postprandial glucose levels.1,2

PHARMACOKINETICS — The extended-release (ER) formulation releases exenatide from microspheres over a period of about 10 weeks. The initial release is from the surface of the microspheres, followed by a more gradual release from the microspheres themselves, resulting in 2 peaks ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
Article code: 1386b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian